Palivizumab immunoprophylaxis for infants with BPD has medium- and long-term benefits: myth or maxim?

It is uncertain whether immunoprophylaxis against RSV protects preterm babies with BPD against future respiratory problems. It is biologically plausible that it does, at least in some infants. https://bit.ly/3ikzwZD

Detalles Bibliográficos
Autores principales: Quinn, Lauren A., Hirani, Sunaya H., Williams, Thomas C., Sinha, Ian P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753667/
https://www.ncbi.nlm.nih.gov/pubmed/35035568
http://dx.doi.org/10.1183/20734735.0110-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753667/
https://www.ncbi.nlm.nih.gov/pubmed/35035568
http://dx.doi.org/10.1183/20734735.0110-2021

Ejemplares similares